Epstein-Barr Virus Antibodies Targeting Glycoprotein 350

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Epstein-Barr virus (EBV) infections, particularly in immunosuppressed patients post-transplant, are inadequate due to the lack of effective therapies that specifically target EBV+ cells, leading to aggressive complications like post-transplant lymphoproliferative diseases (PTLDs), and existing vaccines have not elicited sterilizing immunity.

Innovation Solution

Development of EBV-specific antibodies and immunogenic peptides that bind to EBV glycoprotein 350/220, as well as antibody-small molecule conjugates, to neutralize EBV infection and prevent PTLD development, including humanized antibodies like 72A1 and E1D1, and their use in pharmaceutical compositions for therapeutic and prophylactic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-specific treatments (radiation/chemotherapy) are used to treat EBV+ PTLD cases, then tumor cells are destroyed, but healthy cells are damaged and side effects occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses EBV-specific antibodies as intermediaries that selectively bind to EBV-infected cells through EBV antigens on the viral surface. These antibodies mediate targeted destruction of infected cells via Fc-mediated mechanisms (ADCC, ADC, CDC) without directly contacting or damaging healthy cells, thus resolving the contradiction between effective tumor destruction and minimizing side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces non-specific mechanical/chemical destruction (radiation/chemotherapy) with a biological recognition system where antibodies specifically recognize EBV antigens on infected cells. This substitution enables selective targeting based on molecular recognition rather than blanket destruction, achieving effective treatment with reduced harm to healthy tissues

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If CD20 antibodies are used to treat EBV+ PTLD cases, then EBV-infected B cells are targeted, but healthy B cells are also destroyed and the immune system is weakened

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune system function

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces EBV-specific antibodies as a new intermediary that targets EBV antigens rather than B cell surface markers like CD20. This intermediary approach allows selective destruction of EBV-infected cells while preserving healthy B cells that lack EBV antigens, thus maintaining immune system function while achieving treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies the principle of local quality by directing the therapeutic action specifically to cells expressing EBV antigens rather than all B cells expressing CD20. The antibody therapy exhibits localized effectiveness only where EBV antigens are present, preserving the quality and function of healthy B cells while eliminating infected ones

Inventive Principle:

Principle #3Local quality

3Reliability

If reduction of immunosuppression is used to treat EBV+ PTLD cases, then EBV-infected cell proliferation is controlled, but graft-versus-host disease occurs

Engineering Contradiction:

ImproveEBV infection controlVSAvoidgraft-versus-host disease

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses EBV-specific antibodies as intermediaries that directly neutralize and eliminate EBV-infected cells without requiring modulation of the overall immunosuppressive regimen. This intermediary approach controls EBV infection through antibody-mediated mechanisms while maintaining the necessary immunosuppression to prevent graft-versus-host disease

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts the EBV infection problem from the broader immunosuppression context by specifically targeting and removing EBV-infected cells through antibody therapy. This extraction allows control of EBV proliferation without needing to reduce overall immunosuppression levels, thereby avoiding the harmful effect of graft-versus-host disease

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These EBV-specific antibodies and conjugates effectively neutralize EBV infection, reduce the risk of PTLD, and offer potential for immunization against EBV-associated cancers, providing a targeted approach to managing EBV infections in immunosuppressed patients.

Implementation Method 1

the EBV antibody or an immunogenic fragment thereof specifically binds to EBV glycoprotein 350/220

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS12012446B2Epstein-Barr virus antibodies and uses thereof

Publication Date: 2024.06.18 CITY OF HOPE

AI summary

Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more immunogenic peptides. Also disclosed are immunogenic peptides comprising fragments of gp350 amino acid sequence, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.